DOCSLIB.ORG

Growth Hormone (GH) and the Glomerular Podocyte

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Growth Hormone (GH) and the Glomerular Podocyte A dissertation presented to the faculty of the College of Arts and Sciences of Ohio University In partial fulfillment of the requirements for the degree Doctor of Philosophy Alison L. Brittain May 2019 © 2019 Alison L. Brittain. All Rights Reserved. 2 This dissertation titled Growth Hormone (GH) and the Glomerular Podocyte by ALISON L. BRITTAIN has been approved for the Department of Biological Sciences and the College of Arts and Sciences by John J. Kopchick Goll-Ohio Professor of Molecular Biology Joseph Shields Interim Dean, College of Arts and Sciences 3 ABSTRACT BRITTAIN, ALISON L., Ph.D., May 2019, Biological Sciences Growth Hormone (GH) and the Glomerular Podocyte Director of Dissertation: John J. Kopchick Growth Hormone (GH) is a peptide hormone secreted from the anterior pituitary that has numerous effects on the kidney. In mice, excess GH is associated with the development of glomerular disease. The glomerulus is the most proximal part of the nephron and contains several different cell types, including the podocyte, which forms part of the filtration barrier between the blood and urine. Previous literature suggests that in vitro, GH may damage the podocyte when administered at high levels. Whether these damaging effects exist in vivo has yet to be determined and is part of the focus of this dissertation. Discussed within this work is a thorough review of the role of GH in the renal system and podocyte physiology. These chapters are followed by a study examining the effects of differing GH concentrations on mouse and human podocytes in vitro, which highlight an ability for GH to induce a moderate amount of epithelial-to-mesenchymal transition (EMT) at 50 ng/mL while reducing apoptosis and cellular viability. The next chapter of this dissertation details the characterization of a novel mouse model: the podocyte-specific GHR gene “knockdown” mouse (PodGHR-/-). The PodGHR-/- mouse was developed and studied under three conditions: the normal aging C57BL6/J phenotype, transgenic bovine (b) GH overexpression, and streptozotocin (STZ)-induced diabetes. Studies of the PodGHR-/- mouse over the course of normal aging showed detrimental changes to the kidney in male mice in the form of increased glomerular 4 filtration rate (GFR), glomerular volume and albumin to creatinine ratio (ACR). When crossed with the bovine GH (bGH) overproducing mouse, PodGHR-/- double transgenic mice (bPodGHR-/-) exhibited decreased gene expression markers of renal damage along with decreased fluid retention, suggestive of some renoprotection. However, female bPodGHR-/- mice exhibited none of these changes but showed increased kidney hydroxyproline content at young and old age which was not associated with other markers of renal decline. When induced to diabetes with STZ, male PodGHR-/- mice did not exhibit overt changes in renal physiology, but also did not exhibit the decreases in podocyte foot process number or increases in foot process width that were seen in wild- type (WT) diabetic mice. The final study of this dissertation examined datasets to determine GH receptor (GHR) gene expression levels in chronic kidney diseases. This study concluded that GHR and insulin-like growth factor 1 (IGF1) gene expression levels are generally decreased in human and mouse models of chronic kidney disease, while IGFBP6 gene expression levels are generally increased. Cumulatively, the studies detailed in this dissertation suggest GH action through the podocyte plays a nuanced role in normal renal physiology and in the development of renal disease, being beneficial to the podocyte in some cases and detrimental in others. 5 PREFACE Many of the chapters of this dissertation are manuscripts in preparation for submission, including chapters 4, 5 and 6. Each of these chapters has a corresponding section in the appendix with supplemental materials, appendices A-C. Chapters 1, 2, 3 and 7 represent stand-alone bodies of work. Chapter 1 and 2 provide a thorough background into growth hormone, its impacts on general renal function and on specific podocyte function. 6 ACKNOWLEDGMENTS To my mentor and director of our laboratory, John Kopchick. I am grateful for your encouragement, kindness and endless support in achieving my goals. To Darlene Berryman, thanks for your friendship and your example as a leader at OUHCOM. To Nick Okada, who I appreciate for his broad knowledge of medical endocrinology and our chats about the difficulties of learning and teaching medicine. To Ed List, whose insight into both scientific and non-scientific predicaments is invaluable. To my fellow graduate students in the Kopchick Laboratory: Silvana Duran-Ortiz, Jonathan Young, Elizabeth Jensen, Kevin Funk, Colin Kruse, Prateek Kulkarni, Mat Buchman, Katie Troike. You made getting a Ph.D. fun… I can’t imagine a better group of people to work with. To post-doctoral researchers Reetobrata Basu and Yanrong Qian, I am grateful for not only your superior scientific insight and technical laboratory skills, but your kindness and friendship over the last four years. I would also like to thank the staff at the Edison Biotechnology Institute. To Lorianne Abdella, Rachel Beha, and the army of students at the front desk at EBI, thank you for everything you do day in and day out to keep our laboratory running. Thanks also goes to the staff of Laboratory Animal Resources, Ed, Eric, Nate, Darla and Tammy. I appreciate your efforts in keeping our mice happy and healthy. Another group of individuals essential to completion of this dissertation were the staff and faculty at OU and OU-HCOM. Thanks go to Julie Buckley at the Histopathology CORE, who assisted in preparing many of my samples for histology, and to Michelle Pate for her assistance with FACS sorting. Thanks also to Ramiro Malgor 7 and Mark Berryman for their histology expertise and guidance. Special thanks also to Karen Coschigano for her feedback and support on this project, and Jeff Thuma for his microscopy expertise. Thank you is also due to Ram Menon of University of Michigan, who supported this project with his clinical insight and expertise in podocyte biology. I would also like to extend a huge thanks to Ryan Woodyard, who worked with me to collect a large portion of the data presented in this project. This project would not have been completed without his help. To my mom, for her support and encouragement during all times, good and bad. To my dad, for encouraging my love of science from a young age. Also, to my sister Melissa and my brother Chris for their lighthearted support. And finally, to my wife Laura, whose intelligence improves my work and whose love improves my life. 8 TABLE OF CONTENTS Page Abstract ............................................................................................................................... 3 Preface................................................................................................................................. 5 Acknowledgments............................................................................................................... 6 List of Tables .................................................................................................................... 10 List of Figures ................................................................................................................... 11 Chapter 1: Growth Hormone (GH) and Renal Function ................................................... 15 Physiology of GH ......................................................................................................... 15 GH and General Renal Function ................................................................................... 21 The Glomerulus ............................................................................................................ 25 GH and Glomerular Function ....................................................................................... 30 GH and Diabetic Nephropathy ..................................................................................... 32 Concluding Remarks ..................................................................................................... 37 Chapter 2: GH and the Podocyte ...................................................................................... 39 The Podocyte ................................................................................................................ 39 Known Mechanisms of GH-Induced Podocyte Damage .............................................. 45 Potential Mechanisms of GH-Induced Podocyte Damage ........................................... 48 Concluding Remarks ..................................................................................................... 57 Chapter 3: Specific Aims .................................................................................................. 59 Chapter 4: The Effect of Varying GH Concentration on Podocyte Health In Vitro ......... 61 Abstract ......................................................................................................................... 61 Introduction ................................................................................................................... 62 Methods ........................................................................................................................ 64 Results ........................................................................................................................... 70 Discussion ....................................................................................................................
Recommended publications
  • The Switch from Fermentation to Respiration in Saccharomyces Cerevisiae Is Regulated by the Ert1 Transcriptional Activator/Repressor

    The Switch from Fermentation to Respiration in Saccharomyces Cerevisiae Is Regulated by the Ert1 Transcriptional Activator/Repressor

    INVESTIGATION The Switch from Fermentation to Respiration in Saccharomyces cerevisiae Is Regulated by the Ert1 Transcriptional Activator/Repressor Najla Gasmi,* Pierre-Etienne Jacques,† Natalia Klimova,† Xiao Guo,§ Alessandra Ricciardi,§ François Robert,†,** and Bernard Turcotte*,‡,§,1 ‡Department of Medicine, *Department of Biochemistry, and §Department of Microbiology and Immunology, McGill University Health Centre, McGill University, Montreal, QC, Canada H3A 1A1, †Institut de recherches cliniques de Montréal, Montréal, QC, Canada H2W 1R7, and **Département de Médecine, Faculté de Médecine, Université de Montréal, QC, Canada H3C 3J7 ABSTRACT In the yeast Saccharomyces cerevisiae, fermentation is the major pathway for energy production, even under aerobic conditions. However, when glucose becomes scarce, ethanol produced during fermentation is used as a carbon source, requiring a shift to respiration. This adaptation results in massive reprogramming of gene expression. Increased expression of genes for gluconeogenesis and the glyoxylate cycle is observed upon a shift to ethanol and, conversely, expression of some fermentation genes is reduced. The zinc cluster proteins Cat8, Sip4, and Rds2, as well as Adr1, have been shown to mediate this reprogramming of gene expression. In this study, we have characterized the gene YBR239C encoding a putative zinc cluster protein and it was named ERT1 (ethanol regulated transcription factor 1). ChIP-chip analysis showed that Ert1 binds to a limited number of targets in the presence of glucose. The strongest enrichment was observed at the promoter of PCK1 encoding an important gluconeogenic enzyme. With ethanol as the carbon source, enrichment was observed with many additional genes involved in gluconeogenesis and mitochondrial function. Use of lacZ reporters and quantitative RT-PCR analyses demonstrated that Ert1 regulates expression of its target genes in a manner that is highly redundant with other regulators of gluconeogenesis.
  • The Interactome of KRAB Zinc Finger Proteins Reveals the Evolutionary History of Their Functional Diversification

    The Interactome of KRAB Zinc Finger Proteins Reveals the Evolutionary History of Their Functional Diversification

    Resource The interactome of KRAB zinc finger proteins reveals the evolutionary history of their functional diversification Pierre-Yves Helleboid1,†, Moritz Heusel2,†, Julien Duc1, Cécile Piot1, Christian W Thorball1, Andrea Coluccio1, Julien Pontis1, Michaël Imbeault1, Priscilla Turelli1, Ruedi Aebersold2,3,* & Didier Trono1,** Abstract years ago (MYA) (Imbeault et al, 2017). Their products harbor an N-terminal KRAB (Kru¨ppel-associated box) domain related to that of Krüppel-associated box (KRAB)-containing zinc finger proteins Meisetz (a.k.a. PRDM9), a protein that originated prior to the diver- (KZFPs) are encoded in the hundreds by the genomes of higher gence of chordates and echinoderms, and a C-terminal array of zinc vertebrates, and many act with the heterochromatin-inducing fingers (ZNF) with sequence-specific DNA-binding potential (Urru- KAP1 as repressors of transposable elements (TEs) during early tia, 2003; Birtle & Ponting, 2006; Imbeault et al, 2017). KZFP genes embryogenesis. Yet, their widespread expression in adult tissues multiplied by gene and segment duplication to count today more and enrichment at other genetic loci indicate additional roles. than 350 and 700 representatives in the human and mouse Here, we characterized the protein interactome of 101 of the ~350 genomes, respectively (Urrutia, 2003; Kauzlaric et al, 2017). A human KZFPs. Consistent with their targeting of TEs, most KZFPs majority of human KZFPs including all primate-restricted family conserved up to placental mammals essentially recruit KAP1 and members target sequences derived from TEs, that is, DNA trans- associated effectors. In contrast, a subset of more ancient KZFPs posons, ERVs (endogenous retroviruses), LINEs, SINEs (long and rather interacts with factors related to functions such as genome short interspersed nuclear elements, respectively), or SVAs (SINE- architecture or RNA processing.
  • Assessment Report

    Assessment Report

    15 November 2018 EMA/CHMP/845216/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Macimorelin Aeterna Zentaris International non-proprietary name: macimorelin Procedure No. EMEA/H/C/004660/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 6 1.1. Submission of the dossier ...................................................................................... 6 1.2. Steps taken for the assessment of the product ......................................................... 7 2. Scientific discussion ................................................................................ 8 2.1. Problem statement ............................................................................................... 8 2.1.1. Disease or condition ........................................................................................... 8 2.1.1. Epidemiology .................................................................................................... 8 2.1.2. Aetiology and pathogenesis ...............................................................................
  • A Negative Feedback Loop of the TOR Signaling Moderates Growth And

    A Negative Feedback Loop of the TOR Signaling Moderates Growth And

    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.06.284745; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 A negative feedback loop of the TOR signaling moderates 2 growth and enables rapid sensing of stress signals in plants 3 Muhammed Jamsheer K1#*<, Sunita Jindal1#>, Mohan Sharma1, Manvi Sharma1, Sreejath Sivaj2, 4 Chanchal Thomas Mannully1^, Ashverya Laxmi1* 5 1National Institute of Plant Genome Research, Aruna Asaf Ali Marg, New Delhi 110067, India 6 2Department of Mechanical Engineering, Indian Institute of Technology Delhi, New Delhi, 110016, 7 India 8 9 <Current affiliation: Amity Food & Agriculture Foundation, Amity University Uttar Pradesh, Sector 10 125, Noida 201313, India 11 ^Current affiliation: Cell Metabolism Laboratory, School of Pharmacy, The Hebrew University of 12 Jerusalem, Jerusalem, 9112102, Israel 13 >Current affiliation: Department of Molecular Biology and Radiology, Mendel University in Brno, 14 Brno, 613 00, Czech Republic 15 16 #Equal first authors 17 18 *Corresponding authors 19 Ashverya Laxmi 20 Muhammed Jamsheer K 21 Email: AL: [email protected] (Lead Contact); MJK: [email protected] 22 ORCID: Ashverya Laxmi (0000-0002-3430-4200); Muhammed Jamsheer K (0000-0002-2135- 23 8760) 24 25 26 27 28 29 30 31 32 33 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.09.06.284745; this version posted September 7, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved.
  • Supplemental Table 3 Site ID Intron Poly(A) Site Type NM/KG Inum

    Supplemental Table 3 Site ID Intron Poly(A) Site Type NM/KG Inum

    Supplemental Table 3 Site ID Intron Poly(A) site Type NM/KG Inum Region Gene ID Gene Symbol Gene Annotation Hs.120277.1.10 chr3:170997234:170996860 170996950 b NM_153353 7 CDS 151827 LRRC34 leucine rich repeat containing 34 Hs.134470.1.27 chr17:53059664:53084458 53065543 b NM_138962 10 CDS 124540 MSI2 musashi homolog 2 (Drosophila) Hs.162889.1.18 chr14:80367239:80329208 80366262 b NM_152446 12 CDS 145508 C14orf145 chromosome 14 open reading frame 145 Hs.187898.1.27 chr22:28403623:28415294 28404458 b NM_181832 16 3UTR 4771 NF2 neurofibromin 2 (bilateral acoustic neuroma) Hs.228320.1.6 chr10:115527009:115530350 115527470 b BC036365 5 CDS 79949 C10orf81 chromosome 10 open reading frame 81 Hs.266308.1.2 chr11:117279579:117278191 117278967 b NM_032046 12 CDS 84000 TMPRSS13 transmembrane protease, serine 13 Hs.266308.1.4 chr11:117284536:117281662 117283722 b NM_032046 9 CDS 84000 TMPRSS13 transmembrane protease, serine 13 Hs.2689.1.4 chr10:53492398:53563605 53492622 b NM_006258 7 CDS 5592 PRKG1 protein kinase, cGMP-dependent, type I Hs.280781.1.6 chr18:64715646:64829150 64715837 b NM_024781 4 CDS 79839 C18orf14 chromosome 18 open reading frame 14 Hs.305985.2.25 chr12:8983686:8984438 8983942 b BX640639 17 3UTR NA NA NA Hs.312098.1.36 chr1:151843991:151844258 151844232 b NM_003815 15 CDS 8751 ADAM15 a disintegrin and metalloproteinase domain 15 (metargidin) Hs.314338.1.11 chr21:39490293:39481214 39487623 b NM_018963 41 CDS 54014 BRWD1 bromodomain and WD repeat domain containing 1 Hs.33368.1.3 chr15:92685158:92689361 92688314 b NM_018349 6 CDS 55784 MCTP2 multiple C2-domains with two transmembrane regions 2 Hs.346736.1.21 chr2:99270738:99281614 99272414 b AK126402 10 3UTR 51263 MRPL30 mitochondrial ribosomal protein L30 Hs.445061.1.19 chr16:69322898:69290216 69322712 b NM_018052 14 CDS 55697 VAC14 Vac14 homolog (S.
  • Prior Authorization Criteria

    Prior Authorization Criteria

    PRIOR AUTHORIZATION CRITERIA Last Updated 09/01/2021 This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered under your medical or prescription drug benefit. Please verify drug coverage by checking your formulary and member handbook. Additional restrictions and exclusions may apply. If you have questions, please contact Providence Health Plan Customer Service at 503-574-7500 or 1-800-878-4445 (TTY: 711). Service is available five days a week, Monday through Friday, between 8 a.m. and 6 p.m. ACTINIC KERATOSIS AGENTS MEDICATION(S) CARAC, FLUOROURACIL 0.5% CREAM, IMIQUIMOD 3.75% CREAM, IMIQUIMOD 3.75% CREAM PUMP, KLISYRI, PICATO, TOLAK, ZYCLARA COVERED USES N/A EXCLUSION CRITERIA • Treatment of basal cell carcinoma or other skin cancers REQUIRED MEDICAL INFORMATION 1. For the treatment of Actinic Keratosis (AK): Documentation of trial and failure*, contraindication or intolerance to two of the following formulary, generic topical agents: a. Diclofenac 3% gel b. 5-fluorouracil 2% or 5% cream/solution c. Imiquimod 5% cream *An adequate trial and failure is defined as failure to achieve clearance of AK lesion(s) after adherence to recommended treatment dosing and duration Reauthorization: Requires documentation of a reduction in the number and/or size of lesions of AK and medical rationale for continuing therapy beyond recommended treatment course. 1. For the treatment of external genital and perianal warts/condyloma acuminate (Zyclara® 3.75% only): Documentation of trial and failure*, contraindication, or intolerance to formulary, generic imiquimod 5% cream.
  • Growth Hormone Secretagogues: History, Mechanism of Action and Clinical Development

    Growth Hormone Secretagogues: History, Mechanism of Action and Clinical Development

    Growth hormone secretagogues: history, mechanism of action and clinical development Junichi Ishida1, Masakazu Saitoh1, Nicole Ebner1, Jochen Springer1, Stefan D Anker1, Stephan von Haehling 1 , Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany Abstract Growth hormone secretagogues (GHSs) are a generic term to describe compounds which increase growth hormone (GH) release. GHSs include agonists of the growth hormone secretagogue receptor (GHS‐R), whose natural ligand is ghrelin, and agonists of the growth hormone‐releasing hormone receptor (GHRH‐R), to which the growth hormone‐ releasing hormone (GHRH) binds as a native ligand. Several GHSs have been developed with a view to treating or diagnosisg of GH deficiency, which causes growth retardation, gastrointestinal dysfunction and altered body composition, in parallel with extensive research to identify GHRH, GHS‐R and ghrelin. This review will focus on the research history and the pharmacology of each GHS, which reached randomized clinical trials. Furthermore, we will highlight the publicly disclosed clinical trials regarding GHSs. Address for correspondence: Corresponding author: Stephan von Haehling, MD, PhD Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany Robert‐Koch‐Strasse 40, 37075 Göttingen, Germany, Tel: +49 (0) 551 39‐20911, Fax: +49 (0) 551 39‐20918 E‐mail: [email protected]‐goettingen.de Key words: GHRPs, GHSs, Ghrelin, Morelins, Body composition, Growth hormone deficiency, Received 10 September 2018 Accepted 07 November 2018 1. Introduction testing in clinical trials. A vast array of indications of ghrelin receptor agonists has been evaluated including The term growth hormone secretagogues growth retardation, gastrointestinal dysfunction, and (GHSs) embraces compounds that have been developed altered body composition, some of which have received to increase growth hormone (GH) release.
  • Supplementary Table 1

    Supplementary Table 1

    Supplementary Table 1. 492 genes are unique to 0 h post-heat timepoint. The name, p-value, fold change, location and family of each gene are indicated. Genes were filtered for an absolute value log2 ration 1.5 and a significance value of p ≤ 0.05. Symbol p-value Log Gene Name Location Family Ratio ABCA13 1.87E-02 3.292 ATP-binding cassette, sub-family unknown transporter A (ABC1), member 13 ABCB1 1.93E-02 −1.819 ATP-binding cassette, sub-family Plasma transporter B (MDR/TAP), member 1 Membrane ABCC3 2.83E-02 2.016 ATP-binding cassette, sub-family Plasma transporter C (CFTR/MRP), member 3 Membrane ABHD6 7.79E-03 −2.717 abhydrolase domain containing 6 Cytoplasm enzyme ACAT1 4.10E-02 3.009 acetyl-CoA acetyltransferase 1 Cytoplasm enzyme ACBD4 2.66E-03 1.722 acyl-CoA binding domain unknown other containing 4 ACSL5 1.86E-02 −2.876 acyl-CoA synthetase long-chain Cytoplasm enzyme family member 5 ADAM23 3.33E-02 −3.008 ADAM metallopeptidase domain Plasma peptidase 23 Membrane ADAM29 5.58E-03 3.463 ADAM metallopeptidase domain Plasma peptidase 29 Membrane ADAMTS17 2.67E-04 3.051 ADAM metallopeptidase with Extracellular other thrombospondin type 1 motif, 17 Space ADCYAP1R1 1.20E-02 1.848 adenylate cyclase activating Plasma G-protein polypeptide 1 (pituitary) receptor Membrane coupled type I receptor ADH6 (includes 4.02E-02 −1.845 alcohol dehydrogenase 6 (class Cytoplasm enzyme EG:130) V) AHSA2 1.54E-04 −1.6 AHA1, activator of heat shock unknown other 90kDa protein ATPase homolog 2 (yeast) AK5 3.32E-02 1.658 adenylate kinase 5 Cytoplasm kinase AK7
  • Transcriptomic Regulation of Alternative Phenotypic Trajectories in Embryos of the Annual Killifish Austrofundulus Limnaeus

    Transcriptomic Regulation of Alternative Phenotypic Trajectories in Embryos of the Annual Killifish Austrofundulus Limnaeus

    Portland State University PDXScholar Dissertations and Theses Dissertations and Theses Fall 11-30-2017 Transcriptomic Regulation of Alternative Phenotypic Trajectories in Embryos of the Annual Killifish Austrofundulus limnaeus Amie L. Romney Portland State University Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds Part of the Biology Commons, and the Genetics and Genomics Commons Let us know how access to this document benefits ou.y Recommended Citation Romney, Amie L., "Transcriptomic Regulation of Alternative Phenotypic Trajectories in Embryos of the Annual Killifish Austrofundulus limnaeus" (2017). Dissertations and Theses. Paper 4033. https://doi.org/10.15760/etd.5917 This Dissertation is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: [email protected]. Transcriptomic Regulation of Alternative Phenotypic Trajectories in embryos of the Annual Killifish Austrofundulus limnaeus by Amie Lynn Thomas Romney A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biology Dissertation Committee Jason Podrabsky, Chair Suzanne Estes Bradley Buckley Todd Rosenstiel Dirk Iwata-Reuyl Portland State University 2017 © 2017 Amie Lynn Thomas Romney ABSTRACT The Annual Killifish, Austrofundulus limnaeus, survives the seasonal drying of their pond habitat in the form of embryos entering diapause midway through development. The diapause trajectory is one of two developmental phenotypes. Alternatively, individuals can “escape” entry into diapause and develop continuously until hatching. The alternative phenotypes of A. limnaeus are a form of developmental plasticity that provides this species with a physiological adaption for surviving stressful environments.
  • 2020 Medicaid Preapproval Criteria

    2020 Medicaid Preapproval Criteria

    2020 Medicaid Preapproval Criteria ABILIFY MAINTENA ................................................................................................................................................................ 10 ACTHAR HP ............................................................................................................................................................................ 11 ACTIMMUNE ......................................................................................................................................................................... 13 ADCIRCA ................................................................................................................................................................................ 14 ADEMPAS .............................................................................................................................................................................. 15 ADENOSINE DEAMINASE (ADA) REPLACEMENT ................................................................................................................... 17 AFINITOR ............................................................................................................................................................................... 18 AFINITOR DISPERZ ................................................................................................................................................................. 19 ALDURAZYME .......................................................................................................................................................................
  • Supplementary Table 3 Gene Microarray Analysis: PRL+E2 Vs

    Supplementary Table 3 Gene Microarray Analysis: PRL+E2 Vs

    Supplementary Table 3 Gene microarray analysis: PRL+E2 vs. control ID1 Field1 ID Symbol Name M Fold P Value 69 15562 206115_at EGR3 early growth response 3 2,36 5,13 4,51E-06 56 41486 232231_at RUNX2 runt-related transcription factor 2 2,01 4,02 6,78E-07 41 36660 227404_s_at EGR1 early growth response 1 1,99 3,97 2,20E-04 396 54249 36711_at MAFF v-maf musculoaponeurotic fibrosarcoma oncogene homolog F 1,92 3,79 7,54E-04 (avian) 42 13670 204222_s_at GLIPR1 GLI pathogenesis-related 1 (glioma) 1,91 3,76 2,20E-04 65 11080 201631_s_at IER3 immediate early response 3 1,81 3,50 3,50E-06 101 36952 227697_at SOCS3 suppressor of cytokine signaling 3 1,76 3,38 4,71E-05 16 15514 206067_s_at WT1 Wilms tumor 1 1,74 3,34 1,87E-04 171 47873 238623_at NA NA 1,72 3,30 1,10E-04 600 14687 205239_at AREG amphiregulin (schwannoma-derived growth factor) 1,71 3,26 1,51E-03 256 36997 227742_at CLIC6 chloride intracellular channel 6 1,69 3,23 3,52E-04 14 15038 205590_at RASGRP1 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 1,68 3,20 1,87E-04 55 33237 223961_s_at CISH cytokine inducible SH2-containing protein 1,67 3,19 6,49E-07 78 32152 222872_x_at OBFC2A oligonucleotide/oligosaccharide-binding fold containing 2A 1,66 3,15 1,23E-05 1969 32201 222921_s_at HEY2 hairy/enhancer-of-split related with YRPW motif 2 1,64 3,12 1,78E-02 122 13463 204015_s_at DUSP4 dual specificity phosphatase 4 1,61 3,06 5,97E-05 173 36466 227210_at NA NA 1,60 3,04 1,10E-04 117 40525 231270_at CA13 carbonic anhydrase XIII 1,59 3,02 5,62E-05 81 42339 233085_s_at OBFC2A oligonucleotide/oligosaccharide-binding
  • Temporal Endogenous Gene Expression Profiles in Response to Polymer-Mediated Transfection and Profile Comparison to Lipid-Mediated Transfection Timothy M

    Temporal Endogenous Gene Expression Profiles in Response to Polymer-Mediated Transfection and Profile Comparison to Lipid-Mediated Transfection Timothy M

    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Biological Systems Engineering: Papers and Biological Systems Engineering Publications 2015 Temporal endogenous gene expression profiles in response to polymer-mediated transfection and profile comparison to lipid-mediated transfection Timothy M. Martin University of Nebraska Medical Center, [email protected] Sarah A. Plautz University of Nebraska-Lincoln, [email protected] Angela K. Pannier University of Nebraska-Lincoln, [email protected] Follow this and additional works at: https://digitalcommons.unl.edu/biosysengfacpub Part of the Bioresource and Agricultural Engineering Commons, Environmental Engineering Commons, and the Other Civil and Environmental Engineering Commons Martin, Timothy M.; Plautz, Sarah A.; and Pannier, Angela K., "Temporal endogenous gene expression profiles in response to polymer-mediated transfection and profile comparison to lipid-mediated transfection" (2015). Biological Systems Engineering: Papers and Publications. 518. https://digitalcommons.unl.edu/biosysengfacpub/518 This Article is brought to you for free and open access by the Biological Systems Engineering at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Biological Systems Engineering: Papers and Publications by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. Published in The Journal of Gene Medicine 17 (2015), pp. 33–53. doi 10.1002/jgm.2822 PMID: 25663627 Copyright © 2015 John Wiley & Sons, Ltd. Used by permission Submitted 17 November 2014; revised 1 February 2015; accepted 3 February 2015 digitalcommons.unl.edu Temporal endogenous gene expression profiles in response to polymer-mediated transfection and profile comparison to lipid-mediated transfection Timothy M. Martin,1 Sarah A. Plautz,2 and Angela K.